<?xml version="1.0" encoding="UTF-8"?>
<!-- generated by CLiX/Wiki2XML [MPI-Inf, MMCI@UdS] $LastChangedRevision: 92 $ on 16.04.2009 19:16:15[mciao0827] -->
<!DOCTYPE article SYSTEM "../article.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
<header>
<title>Number needed to treat</title>
<id>1964571</id>
<revision>
<id>239932901</id>
<timestamp>2008-09-21T04:25:56Z</timestamp>
<contributor>
<username>WhatamIdoing</username>
<id>1998764</id>
</contributor>
</revision>
<categories>
<category>Epidemiology</category>
<category>Pharmacology</category>
</categories>
</header>
<bdy>

The <b>number needed to treat</b> (NNT) is an <link xlink:type="simple" xlink:href="../997/66997.xml">
epidemiological</link> measure used in assessing the effectiveness of a health-care intervention, typically a treatment with <link xlink:type="simple" xlink:href="../121/180121.xml">
medication</link>. The NNT is the number of patients who need to be treated in order to prevent one additional bad outcome (i.e. to reduce the expected number of cases of a defined endpoint by one).  It is defined as the inverse of the <link xlink:type="simple" xlink:href="../699/9594699.xml">
absolute risk reduction</link>. It was described in 1988.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref>
<sec>
<st>
Derivation</st>
<p>

In general, NNT is computed with respect to two treatments <it>A</it> and <it>B</it>, with <it>A</it> typically a drug and <it>B</it> a <link xlink:type="simple" xlink:href="../821/142821.xml">
placebo</link> (e.g., <it>A</it> might be a 5-year treatment with a drug, while <it>B</it> is no treatment). A defined endpoint has to be specified (e.g., the appearance of colon cancer in a five-year period). If the <link xlink:type="simple" xlink:href="../934/22934.xml">
probabilities</link> <it>pA</it> and <it>pB</it> of this endpoint under treatments <it>A</it> and <it>B</it>, respectively, are known, then the NNT is computed as 1/(<it>pB</it> – <it>pA</it>).</p>

</sec>
<sec>
<st>
Relevance</st>
<p>

The NNT is an important measure in <link xlink:type="simple" xlink:href="../424/6989424.xml">
pharmacoeconomics</link>. If a clinical endpoint is devastating enough (<it>e.g.</it> <link xlink:type="simple" xlink:href="../221/8221.xml">
death</link>, <link xlink:type="simple" xlink:href="../969/60969.xml">
heart attack</link>), drugs with a high NNT may still be indicated in particular situations. If the endpoint is minor, <link xlink:type="simple" xlink:href="../201/490201.xml">
health insurers</link> may decline to reimburse drugs with a high NNT.</p>

</sec>
<sec>
<st>
Example: statins for primary prevention</st>
<p>

For example, the ASCOT-LLA manufacturer-sponsored study addressed the benefit of <link xlink:type="simple" xlink:href="../622/634622.xml">
atorvastatin</link> 10 mg (a <link xlink:type="simple" xlink:href="../437/6437.xml">
cholesterol</link>-lowering drug) in patients with <link xlink:type="simple" xlink:href="../432/77432.xml">
hypertension</link> (high blood pressure) but no previous cardiovascular disease (<link xlink:type="simple" xlink:href="../005/3964005.xml">
primary prevention</link>). The trial ran for 3.3 years, and during this period the <link xlink:type="simple" xlink:href="../159/2622159.xml">
relative risk</link> of a "primary event" (heart attack) was reduced by 36%. The <it>absolute</it> risk reduction (ARR), however, was much smaller, because the study group did not have a very high rate of cardiovascular events over the study period: 2.67% in the control group, compared to 1.65% in the treatment group.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref> Taking atorvastatin for 3.3 years, therefore, would lead to an ARR of only 1.02% (2.67% minus 1.65%). The number needed to treat to prevent one cardiovascular event would then be 99.7 for 3.3 years.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%223%22])">3</ref> <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%224%22])">4</ref></p>

</sec>
<sec>
<st>
Worked example</st>

<p>

<table class="wikitable">
<row>
<col>
<b>Abbreviation</b></col>
<col>
<b>Variable</b></col>
<col>
<b>Equation</b></col>
<col>
<b>Value</b></col>
</row>
<row>
<col>
-</col>
<col>
 subjects in <link xlink:type="simple" xlink:href="../288/1640288.xml">
control group</link></col>
<col>
-</col>
<col>
250</col>
</row>
<row>
<col>
-</col>
<col>
subjects in experimental group</col>
<col>
-</col>
<col>
150</col>
</row>
<row>
<col>
-</col>
<col>
events in control group</col>
<col>
-</col>
<col>
100</col>
</row>
<row>
<col>
-</col>
<col>
events in experimental group</col>
<col>
-</col>
<col>
15</col>
</row>
<row>
<col>
CER</col>
<col>
control event rate</col>
<col>
= events / subjects in control group</col>
<col>
0.4, or 40%</col>
</row>
<row>
<col>
EER</col>
<col>
experimental event rate</col>
<col>
= events / subjects in experimental group</col>
<col>
0.1, or 10%</col>
</row>
<row>
<col>
ARR</col>
<col>
 <link>
absolute risk reduction </link>(or increase)</col>
<col>
= CER - EER</col>
<col>
0.3, or 30%</col>
</row>
<row>
<col>
RRR</col>
<col>
 <link xlink:type="simple" xlink:href="../530/9795530.xml">
relative risk reduction</link>(or increase)</col>
<col>
= (CER - EER) / CER</col>
<col>
0.75</col>
</row>
<row>
<col>
NNT</col>
<col>
 <link xlink:type="simple" xlink:href="../571/1964571.xml">
number needed to treat</link>/<link xlink:type="simple" xlink:href="../311/2622311.xml">
number needed to harm</link></col>
<col>
= 1 / ARR</col>
<col>
3.33</col>
</row>
<row>
<col>
OR, RR</col>
<col>
 <link xlink:type="simple" xlink:href="../880/406880.xml">
odds ratio</link>, <link xlink:type="simple" xlink:href="../159/2622159.xml">
relative risk</link>(not really identical, but similar -- see articles for details)</col>
<col>
= CER / EER</col>
<col>
4</col>
</row>
</table>
</p>
<p>

The relative risk (odds ratio) is .25 in the example above.  It is always 1-relative risk reduction, or vice versa.</p>

</sec>
<sec>
<st>
See also</st>
<p>

<list>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../311/2622311.xml">
Number needed to harm</link> - the converse for <link xlink:type="simple" xlink:href="../961/1474961.xml">
side-effect</link>s</entry>
</list>
</p>

</sec>
<sec>
<st>
References</st>

<p>

<reflist>
<entry id="1">
 <cite style="font-style:normal">Laupacis A, Sackett DL, Roberts RS&#32;(1988).&#32;"An assessment of clinically useful measures of the consequences of treatment". <it>N. Engl. J. Med.</it>&#32;<b>318</b>&#32;(26): 1728–33. PMID 3374545.</cite>&nbsp;</entry>
<entry id="2">
 <cite style="font-style:normal">Sever PS, Dahlöf B, Poulter NR, et al&#32;(2003).&#32;"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial". <it>Lancet</it>&#32;<b>361</b>&#32;(9364): 1149–58. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1016%2FS0140-6736%2803%2912948-0">
10.1016/S0140-6736(03)12948-0</weblink>. PMID 12686036.</cite>&nbsp;</entry>
<entry id="3">
"<weblink xlink:type="simple" xlink:href="http://www.jr2.ox.ac.uk/bandolier/booth/cardiac/statascot.html">
Bandolier - Statin effectiveness: ASCOT update</weblink>".&#32;Retrieved on <link>
2008-03-31</link>.</entry>
<entry id="4">
"<weblink xlink:type="simple" xlink:href="http://www.businessweek.com/magazine/content/08_04/b4068052092994.htm?chan=search">
Do Cholesterol Drugs Do Any Good?</weblink>", <link xlink:type="simple" xlink:href="../157/945157.xml">
Business Week</link>.&#32;Retrieved on <link>
2008-03-31</link>.&nbsp;"'That means in a large clinical study, 3% of patients taking a sugar pill or placebo had a heart attack compared to 2% of patients taking Lipitor.' ... The numbers in that sentence mean that for every 100 people in the trial, which lasted 3 1/3 years, three people on placebos and two people on Lipitor had heart attacks.... One fewer heart attack per 100 people. So to spare one person a heart attack, 100 people had to take Lipitor for more than three years. The other 99 got no measurable benefit. Or to put it in terms of a little-known but useful statistic, the number needed to treat (or NNT) for one person to benefit is 100."&nbsp;</entry>
</reflist>
</p>

</sec>
<sec>
<st>
External links</st>
<p>

<list>
<entry level="1" type="bullet">

<weblink xlink:type="simple" xlink:href="http://www.ebem.org/nntcalculator.html">
EBEM's Calculator for NNT</weblink></entry>
<entry level="1" type="bullet">

<weblink xlink:type="simple" xlink:href="http://www.graphpad.com/quickcalcs/NNT1.cfm">
Online Calculator for NNT (GraphPad Software)</weblink> </entry>
</list>
</p>



</sec>
</bdy>
</article>
